POTENTIAL DRUG-DRUG INTERACTIONS IN HEART FAILURE PATIENTS
Open Access
- 25 July 2019
- journal article
- Published by Innovare Academic Sciences Pvt Ltd in International Journal of Pharmacy and Pharmaceutical Sciences
- p. 37-41
Abstract
Objective: The aim of the present study was to assess the prevalence, risk rating and the severity of hazardous pDDIs (potential drug-drug interactions) in the prescribed pharmacotherapy in the hospital discharged heart failure (HF) patients, primarily with co-administered drugs with narrow therapeutic index (statins, anticoagulants, antithrombotic drugs). Methods: The prescriptions of chronic heart failure patients for one year (January-December 2014) were analyzed for pDDIs through Lexi-interact® software. DDIs belonging to the categories D (Consider therapy modification) and X (Avoid combination) and/or severity of drug interaction-major, were selected for the study. Results: After reviewing the medical records of 985 patients, 239 patients were selected based on the criteria mentioned above. The average number of prescription drugs at hospital discharge was 7.27 medications (±1.84 SD) per patient. The total number of pDDIs was 1483 or approximately 6.2 (±3.89 SD) pDDIs per patient. With respect to the risk rating, in categories D and X were detected 76 (5.12 %) and 2 (0.13 %) pDDI, respectively. The major pDDIs were 108 (7.28 %). Conclusion: HF patients are at high risk of pDDIs. Screening of prescriptions for pDDIs and monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety.Keywords
This publication has 19 references indexed in Scilit:
- Conceptualizing multiple drug use in patients with comorbidity and multimorbidity: proposal for standard definitions beyond the term polypharmacyJournal of Clinical Epidemiology, 2019
- Renal organic anion transporters in drug–drug interactions and diseasesEuropean Journal of Pharmaceutical Sciences, 2018
- Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial FibrillationJAMA, 2017
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaCirculation, 2017
- Graves’ Disease and Treatment Effects on Warfarin AnticoagulationCase Reports in Medicine, 2014
- Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyEuropean Heart Journal, 2013
- Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomesJournal of Clinical Epidemiology, 2012
- Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active MetaboliteDrug Metabolism and Disposition, 2010
- Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClinical Pharmacology & Therapeutics, 2006
- The Effects of Allopurinol and Clofibrate on the Elimination of Coumarin Anticoagulants in ManAustralian and New Zealand Journal of Medicine, 1975